Marc Diamond, M.D.

Founding Director, Center for Alzheimer’s and Neurodegenerative Diseases; Distinguished Chair in Basic Brain Injury and Repair, University of Texas Southwestern Medical Center

Marc Diamond, M.D., is the founding Director of the Center for Alzheimer’s and Neurodegenerative Diseases, and is a Professor of Neurology and Neurotherapeutics. Dr. Diamond completed an internship, residency, and chief residency in neurology at the University of California, San Francisco (UCSF) in 1997. After a postdoctoral fellowship, he was a faculty member in the Neurology Department at UCSF from 2002-2009. From 2009-2014 he was the David Clayson Professor of Neurology at Washington University in St. Louis, before he was recruited to UT Southwestern. His research focuses on molecular mechanisms of neurodegeneration in Alzheimer’s disease and related disorders, with the goal of developing novel therapies and diagnostic tools. A therapeutic antibody he co-developed at Washington University in St. Louis is now entering clinical trials for the treatment of dementia. The Center for Alzheimer’s and Neurodegenerative Diseases is comprised of a multidisciplinary group of investigators who are focused on understanding the basis of progressive protein aggregation in human disease. They are using this knowledge to hasten the day when neurodegeneration can be detected presymptomatically and stopped before it causes disability.

Funded Research

These projects were made possible from Cure Alzheimer's Fund support.

Selected Publications

These published papers resulted from Cure Alzheimer’s Fund support.

Marc Diamond The secret sulfate code that lets the bad Tau in, Science Daily, July 13, 2018, Read More

Sarah K. Kaufman, Talitha L. Thomas, Kelly Del Tredici, Heiko Braak, Marc I. Diamond Characterization of tau prion seeding activity and strains from formaldehyde-fixed tissue, Acta Neuropathologica Communications, 5, 7 Jun 2017, 41, Read More

Kiran Yanamandra, Hong Jiang, Thomas E. Mahan, Susan E. Maloney, David F. Wozniak, Marc I. Diamond and David M. Holtzman Anti-tau antibody reduces insoluble tau and decreases brain atrophy, Annals of Clinical and Translational Neurology, 2(3), March 2015, 278–288, Read More